» Articles » PMID: 33495553

Beyond the Storm - Subacute Toxicities and Late Effects in Children Receiving CAR T Cells

Abstract

As clinical advances with chimeric antigen receptor (CAR) T cells are increasingly described and the potential for extending their therapeutic benefit grows, optimizing the implementation of this therapeutic modality is imperative. The recognition and management of cytokine release syndrome (CRS) marked a milestone in this field; however, beyond the understanding gained in treating CRS, a host of additional toxicities and/or potential late effects of CAR T cell therapy warrant further investigation. A multicentre initiative involving experts in paediatric cell therapy, supportive care and/or study of late effects from cancer and haematopoietic stem cell transplantation was convened to facilitate the comprehensive study of extended CAR T cell-mediated toxicities and establish a framework for new systematic investigations of CAR T cell-related adverse events. Together, this group identified six key focus areas: extended monitoring of neurotoxicity and neurocognitive function, psychosocial considerations, infection and immune reconstitution, other end organ toxicities, evaluation of subsequent neoplasms, and strategies to optimize remission durability. Herein, we present the current understanding, gaps in knowledge and future directions of research addressing these CAR T cell-related outcomes. This systematic framework to study extended toxicities and optimization strategies will facilitate the translation of acquired experience and knowledge for optimal application of CAR T cell therapies.

Citing Articles

Cellular Kinetics and Biodistribution of Adoptive T Cell Therapies: from Biological Principles to Effects on Patient Outcomes.

Li R, Grosskopf A, Joslyn L, Stefanich E, Shivva V AAPS J. 2025; 27(2):55.

PMID: 40032717 DOI: 10.1208/s12248-025-01017-w.


New insights into CAR T-cell hematological toxicities: manifestations, mechanisms, and effective management strategies.

Yang Y, Peng H, Wang J, Li F Exp Hematol Oncol. 2024; 13(1):110.

PMID: 39521987 PMC: 11549815. DOI: 10.1186/s40164-024-00573-9.


The winding road: Infectious disease considerations for CAR-T and other novel adoptive cellular therapies in the era of COVID-19.

Singh K, Rocco J, Nussenblatt V Semin Hematol. 2024; 61(5):321-332.

PMID: 39379249 PMC: 11626729. DOI: 10.1053/j.seminhematol.2024.08.002.


Infections associated with CAR-T cell therapy in patients with relapsed refractory multiple myeloma: Risks and prevention strategies.

An J, Zhao J, Zou P, Zhang Y, Wei J, Tian W Cancer Med. 2024; 13(12):e7372.

PMID: 38923216 PMC: 11196838. DOI: 10.1002/cam4.7372.


International recommendations for screening and preventative practices for long-term survivors of transplantation and cellular therapy: a 2023 update.

Rotz S, Bhatt N, Hamilton B, Duncan C, Aljurf M, Atsuta Y Bone Marrow Transplant. 2024; 59(6):717-741.

PMID: 38413823 PMC: 11809468. DOI: 10.1038/s41409-023-02190-2.


References
1.
Curran K, Margossian S, Kernan N, Silverman L, Williams D, Shukla N . Toxicity and response after CD19-specific CAR T-cell therapy in pediatric/young adult relapsed/refractory B-ALL. Blood. 2019; 134(26):2361-2368. PMC: 6933289. DOI: 10.1182/blood.2019001641. View

2.
Sotillo E, Barrett D, Black K, Bagashev A, Oldridge D, Wu G . Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy. Cancer Discov. 2015; 5(12):1282-95. PMC: 4670800. DOI: 10.1158/2159-8290.CD-15-1020. View

3.
Gust J, Taraseviciute A, Turtle C . Neurotoxicity Associated with CD19-Targeted CAR-T Cell Therapies. CNS Drugs. 2018; 32(12):1091-1101. PMC: 7295115. DOI: 10.1007/s40263-018-0582-9. View

4.
Maude S, Laetsch T, Buechner J, Rives S, Boyer M, Bittencourt H . Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018; 378(5):439-448. PMC: 5996391. DOI: 10.1056/NEJMoa1709866. View

5.
Kochenderfer J, Somerville R, Lu T, Yang J, Sherry R, Feldman S . Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy. Mol Ther. 2017; 25(10):2245-2253. PMC: 5628864. DOI: 10.1016/j.ymthe.2017.07.004. View